Open AccessThis article is
- freely available
The Pharmacogenomics of Anti-Hypertensive Therapy
BHF Glasgow Cardiovascular Research Centre, 126 University Place, University of Glasgow, Glasgow G12 8TA, UK
* Author to whom correspondence should be addressed.
Received: 2 March 2010; in revised form: 20 May 2010 / Accepted: 26 May 2010 / Published: 1 June 2010
Abstract: Hypertension is a major public health problem, but measures to reduce blood pressure and thus cardiovascular risk are complicated by the high prevalence of treatment resistance, despite the availability of multiple drugs. Drug side-effects contribute considerably to suboptimal blood pressure control. Clinicians must often rely on empirical methods to match patients with effective drug treatment. Hypertension pharmacogenomics seeks to find genetic predictors of response to drugs that lower blood pressure and to translate this knowledge into clinical practice. In this review we summarise the current status of hypertension pharmacogenetics from monogenic hypertension to essential hypertension and discuss the issues that need to be considered in a hypertension pharmacogenomic study.
Keywords: hypertension; pharmacogenetics; pharmacogenomics; beta-blockers; ACE inhibitors; angiotensin receptor blockers; antihypertensive; calcium channel blockers; thiazide diuretics
Citations to this Article
Cite This Article
MDPI and ACS Style
Padmanabhan, S.; Paul, L.; Dominczak, A.F. The Pharmacogenomics of Anti-Hypertensive Therapy. Pharmaceuticals 2010, 3, 1779-1791.
Padmanabhan S, Paul L, Dominczak AF. The Pharmacogenomics of Anti-Hypertensive Therapy. Pharmaceuticals. 2010; 3(6):1779-1791.
Padmanabhan, Sandosh; Paul, Laura; Dominczak, Anna F. 2010. "The Pharmacogenomics of Anti-Hypertensive Therapy." Pharmaceuticals 3, no. 6: 1779-1791.